Dako's HER2 gene test read with an ordinary microscope, approved in 2011 to help decide on trastuzumab in breast cancer; the FDA records its approval as withdrawn in January 2018.
The HER2 CISH pharmDx Kit from Dako Denmark A/S (Dako is now part of Agilent) was approved on 30 November 2011 (PMA P100024). The FDA approval statement describes dual-colour chromogenic in situ hybridisation, automated on Dako Autostainer instruments, that determines HER2 gene status in breast cancer tissue as an aid in assessing patients for whom trastuzumab is being considered. The FDA's PMA page for the kit gives a withdrawal date of 24 January 2018, and openFDA's copy of the same database gives the original approval the decision code APWD (withdrawal after approval). The FDA companion diagnostic list, last updated on 3 November 2026, still printed the kit.
Dual-colour chromogenic in situ hybridisation with labelled probes for the HER2 gene and the centromere of chromosome 17, giving red and blue signals on the same tissue section that are read under an ordinary bright-field microscope. Connects to HER2.
| Where | Who pays | Help with the cost | |
|---|---|---|---|
| 🇺🇸 United States | Approved 2011 | - | - |
Approval is the regulator's decision for any cancer indication, with the year of the first; it is not a promise that a hospital stocks the drug or that your indication is covered. Not recorded for European Union, United Kingdom, Japan, China, Australia, India: a gap in our research, not a refusal. Compare products across regions.
| Region | Year | Indication |
|---|---|---|
| US | 2011 | HER2 gene status as an aid in selecting trastuzumab in breast cancer · Approval withdrawn on 24 January 2018 (FDA PMA page, withdrawal date; openFDA decision code APWD) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HER2 CISH pharmDx Kit" OR ABSTRACT:"HER2 CISH pharmDx Kit" OR TITLE:"HER2 CISH pharmDx" OR ABSTRACT:"HER2 CISH pharmDx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HER2 CISH pharmDx Kit, not a curated reading list.
Shares HER2 FISH pharmDx Kit, HER2-positive (IHC 3+ or ISH-amplified), HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH), Companion diagnostic and the tag test.
Shares HER2-positive (IHC 3+ or ISH-amplified), HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH), Companion diagnostic, Companion diagnostics and the tag test.
Shares Agilent Technologies (Dako), Companion diagnostic, Companion diagnostics and the tag test.
Shares Agilent Technologies (Dako), Companion diagnostic, Companion diagnostics and the tag test.
Shares Agilent Technologies (Dako), Companion diagnostic, Companion diagnostics and the tag test.
Shares Agilent Technologies (Dako), Companion diagnostics and the tag test.
Shares Companion diagnostic, Companion diagnostics and the tag test.
Shares Companion diagnostic, Companion diagnostics, HER2 and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/